Anti-membrane and anti-spike antibodies are long-lasting and together discriminate between past COVID-19 infection and vaccination
The consequences of past COVID-19 infection for personal health and long-term population immunity are only starting to be revealed. Unfortunately, detecting past infection is currently a challenge, limiting clinical and research endeavors. Widely available anti-SARS-CoV-2 antibody tests cannot differentiate between past infection and vaccination given vaccine-induced anti-spike antibodies and the rapid loss of infection-induced anti-nucleocapsid antibodies. Anti-membrane antibodies develop after COVID-19, but their long-term persistence is unknown. Here, we demonstrate that anti-membrane IgG is a sensitive and specific marker of past COVID-19 infection and persists at least one year. We also confirm that anti-receptor binding domain (RBD) Ig is a long-lasting, sensitive, and specific marker of past infection and vaccination, while anti-nucleocapsid IgG lacks specificity and quickly declines after COVID-19. Thus, a combination of anti-membrane and anti-RBD antibodies can accurately differentiate between distant COVID-19 infection, vaccination, and naïve states to advance public health, individual healthcare, and research goals.
| Errataetall: | |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2021 |
|---|---|
| Enthalten in: |
medRxiv : the preprint server for health sciences - (2021) vom: 08. Nov. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Amjadi, Maya F [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Revised 06.02.2024 published: Electronic UpdateIn: J Infect Dis. 2022 Jun 27;:. - PMID 35758987 Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1101/2021.11.02.21265750 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM333286324 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM333286324 | ||
| 003 | DE-627 | ||
| 005 | 20240206231825.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1101/2021.11.02.21265750 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1282.xml |
| 035 | |a (DE-627)NLM333286324 | ||
| 035 | |a (NLM)34790984 | ||
| 035 | |a (PII)2021.11.02.21265750 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Amjadi, Maya F |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Anti-membrane and anti-spike antibodies are long-lasting and together discriminate between past COVID-19 infection and vaccination |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 06.02.2024 | ||
| 500 | |a published: Electronic | ||
| 500 | |a UpdateIn: J Infect Dis. 2022 Jun 27;:. - PMID 35758987 | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a The consequences of past COVID-19 infection for personal health and long-term population immunity are only starting to be revealed. Unfortunately, detecting past infection is currently a challenge, limiting clinical and research endeavors. Widely available anti-SARS-CoV-2 antibody tests cannot differentiate between past infection and vaccination given vaccine-induced anti-spike antibodies and the rapid loss of infection-induced anti-nucleocapsid antibodies. Anti-membrane antibodies develop after COVID-19, but their long-term persistence is unknown. Here, we demonstrate that anti-membrane IgG is a sensitive and specific marker of past COVID-19 infection and persists at least one year. We also confirm that anti-receptor binding domain (RBD) Ig is a long-lasting, sensitive, and specific marker of past infection and vaccination, while anti-nucleocapsid IgG lacks specificity and quickly declines after COVID-19. Thus, a combination of anti-membrane and anti-RBD antibodies can accurately differentiate between distant COVID-19 infection, vaccination, and naïve states to advance public health, individual healthcare, and research goals | ||
| 650 | 4 | |a Preprint | |
| 700 | 1 | |a Adyniec, Ryan R |e verfasserin |4 aut | |
| 700 | 1 | |a Gupta, Srishti |e verfasserin |4 aut | |
| 700 | 1 | |a Bashar, S Janna |e verfasserin |4 aut | |
| 700 | 1 | |a Mergaert, Aisha M |e verfasserin |4 aut | |
| 700 | 1 | |a Braun, Katarina M |e verfasserin |4 aut | |
| 700 | 1 | |a Moreno, Gage K |e verfasserin |4 aut | |
| 700 | 1 | |a O'Connor, David H |e verfasserin |4 aut | |
| 700 | 1 | |a Friedrich, Thomas C |e verfasserin |4 aut | |
| 700 | 1 | |a Safdar, Nasia |e verfasserin |4 aut | |
| 700 | 1 | |a McCoy, Sara S |e verfasserin |4 aut | |
| 700 | 1 | |a Shelef, Miriam A |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t medRxiv : the preprint server for health sciences |d 2020 |g (2021) vom: 08. Nov. |w (DE-627)NLM310900166 |7 nnns |
| 773 | 1 | 8 | |g year:2021 |g day:08 |g month:11 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1101/2021.11.02.21265750 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2021 |b 08 |c 11 | ||